Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries How Amgen Buying Horizon Therapeutics Could Impact TTAC By: ETF Trends December 12, 2022 at 14:20 PM EST Amgen has agreed to buy Horizon Therapeutics in a deal valued at $27.8 billion. The Thousand Oak, California-based biopharmaceutical company announced on Monday that it will pay $116.50 in cash for each share of Horizon. Based in Dublin, Horizon develops potential treatments for rare, autoimmune, and inflammatory diseases. Horizon manufactures Tepezza, a thyroid eye disease [...] The post How Amgen Buying Horizon Therapeutics Could Impact TTAC appeared first on ETF Trends . Read More >> Related Stocks: Trimtabs Float Shrink ETF Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
How Amgen Buying Horizon Therapeutics Could Impact TTAC By: ETF Trends December 12, 2022 at 14:20 PM EST Amgen has agreed to buy Horizon Therapeutics in a deal valued at $27.8 billion. The Thousand Oak, California-based biopharmaceutical company announced on Monday that it will pay $116.50 in cash for each share of Horizon. Based in Dublin, Horizon develops potential treatments for rare, autoimmune, and inflammatory diseases. Horizon manufactures Tepezza, a thyroid eye disease [...] The post How Amgen Buying Horizon Therapeutics Could Impact TTAC appeared first on ETF Trends . Read More >> Related Stocks: Trimtabs Float Shrink ETF